NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $1.66 +0.07 (+4.40%) Closing price 04:00 PM EasternExtended Trading$1.65 -0.01 (-0.60%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About SELLAS Life Sciences Group Stock (NASDAQ:SLS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SLS alerts:Sign Up Key Stats Today's Range$1.56▼$1.7150-Day Range$1.50▼$2.1952-Week Range$0.77▼$2.27Volume1.80 million shsAverage Volume2.63 million shsMarket Capitalization$165.63 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. Read More SELLAS Life Sciences Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreSLS MarketRank™: SELLAS Life Sciences Group scored higher than 46% of companies evaluated by MarketBeat, and ranked 670th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSELLAS Life Sciences Group has only been the subject of 1 research reports in the past 90 days.Read more about SELLAS Life Sciences Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($0.57) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -4.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSELLAS Life Sciences Group has a P/B Ratio of 12.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SELLAS Life Sciences Group's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.80% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 13.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted27.80% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 13.88%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.75 News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for SELLAS Life Sciences Group this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SLS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows7 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,600.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Stock News HeadlinesSellas Flat on Trial SuccessJuly 16, 2025 | baystreet.caSELLAS gains as mid-stage trial for leukemia drug succeedsJuly 16, 2025 | msn.comNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being quietly opened to the public, and former hedge fund firm manager Whitney Tilson believes this is the best chance in years to turn a small stake into huge gains. He's naming one $10 stock leading this "US: IPO" boom.August 1 at 2:00 AM | Stansberry Research (Ad)SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - NasdaqJuly 9, 2025 | nasdaq.comSellas Life Sciences appoints Linghua Wang to Scientific Advisory BoardJuly 7, 2025 | msn.comSELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory BoardJuly 7, 2025 | globenewswire.comSELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® IndexesJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo FinanceJune 24, 2025 | finance.yahoo.comSee More Headlines SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $1.04 at the beginning of 2025. Since then, SLS shares have increased by 59.6% and is now trading at $1.66. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.04. When did SELLAS Life Sciences Group's stock split? Shares of SELLAS Life Sciences Group reverse split before market open on Friday, November 8th 2019.The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are SELLAS Life Sciences Group's major shareholders? Top institutional investors of SELLAS Life Sciences Group include Blair William & Co. IL (0.02%). View institutional ownership trends. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SELLAS Life Sciences Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include (UNISQ) (UNISQ), Amgen (AMGN), Generex Biotechnology (GNBT), Salesforce (CRM), Bank of America (BAC), Bristol Myers Squibb (BMY) and AbbVie (ABBV). Company Calendar Last Earnings5/13/2025Today8/01/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLS CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees10Year FoundedN/APrice Target and Rating Average Price Target for SELLAS Life Sciences Group$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+321.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-193.67% Return on Assets-113.02% Debt Debt-to-Equity RatioN/A Current Ratio4.64 Quick Ratio4.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book12.77Miscellaneous Outstanding Shares99,777,000Free Float98,380,000Market Cap$165.63 million OptionableNot Optionable Beta2.31 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SLS) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | SponsoredMusk's Big Prediction for 2025Elon Musk just made a bold prediction about 2025—and it could upend the entire tech sector. If he’s right, ...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.